Viral and viral associated mirnas and uses thereof
View Patent ↗Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
1. An isolated nucleic of 45-90 nucleotides in length comprising a sequence selected from the group consisting of:
(a) SEQ ID NO: 269, 308, or 44;
(b) a DNA encoding (a), wherein the DNA is identical in length to (a);
(c) a sequence at least 80% identical to (a) or (b); and
(d) a complement of (a), (b), or (c), wherein the complement is identical in length to the nucleic acid of (a), (b), or (c).
2. An isolated nucleic acid of 18-24 nucleotides in length from the group consisting of:
(a) SEQ ID NO: 1813, 1814, 1891, 1892, 1363, or 1364;
(b) a DNA encoding the nucleic acid of (a), wherein the DNA is identical in length to (a);
(c) a sequence at least 80% identical to (a) or (b); and
(d) a complement of (a), (b), or (c), wherein the complement is identical in length to the nucleic acid of (a), (b), or (c).
3. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of the sequence of the nucleic acid of claim 1 .
4. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of the sequence of the nucleic acid of claim 2 .
5. An isolated nucleic acid of 18-24 nucleotides in length selected from the group consisting of:
(a) a nucleic acid of 18-24 nucleotides in length, wherein SEQ ID NO: 269, 308, or 44 comprises the nucleic acid;
(b) a DNA encoding the nucleic acid of (a), wherein the DNA is identical in length to (a);
(c) a sequence at least 95% identical to (a) or (b); and
(d) a complement of (a), (b), or (c), wherein the complement is identical in length to the nucleic acid of (a), (b), or (c).
6. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of the sequence of the nucleic acid of claim 5 .